Beam Change In Cash vs Stock Based Compensation Analysis

BEAM Stock

USD 30.20 2.68 9.74%

Beam Therapeutics financial indicator trend analysis is way more than just evaluating Beam Therapeutics prevailing accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Beam Therapeutics is a good investment. Please check the relationship between Beam Therapeutics Change In Cash and its Stock Based Compensation accounts. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Beam Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in nation.

To learn how to invest in Beam Stock, please use our How to Invest in Beam Therapeutics guide.

Change In Cash vs Stock Based Compensation

Change In Cash vs Stock Based Compensation Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Beam Therapeutics Change In Cash account and Stock Based Compensation. At this time, the significance of the direction appears to have very week relationship.

The correlation between Beam Therapeutics' Change In Cash and Stock Based Compensation is 0.2. Overlapping area represents the amount of variation of Change In Cash that can explain the historical movement of Stock Based Compensation in the same time period over historical financial statements of Beam Therapeutics, assuming nothing else is changed. The correlation between historical values of Beam Therapeutics' Change In Cash and Stock Based Compensation is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Change In Cash of Beam Therapeutics are associated (or correlated) with its Stock Based Compensation. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Stock Based Compensation has no effect on the direction of Change In Cash i.e., Beam Therapeutics' Change In Cash and Stock Based Compensation go up and down completely randomly.

Correlation Coefficient

0.2

Relationship Direction	Positive
Relationship Strength	Very Weak

View All Relationships

Change In Cash

Stock Based Compensation

Compensation provided to employees in the form of equity or options to purchase company stock. This type of compensation is used to align the interests of employees and shareholders.

Most indicators from Beam Therapeutics' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Beam Therapeutics current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Beam Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in nation.

To learn how to invest in Beam Stock, please use our How to Invest in Beam Therapeutics guide.At this time, Beam Therapeutics' Selling General Administrative is very stable compared to the past year. As of the 11th of December 2024, Tax Provision is likely to grow to about 1.2 M, while Enterprise Value Over EBITDA is likely to drop (12.33).

	2021	2022	2023	2024 (projected)
Total Operating Expenses	444.3M	399.4M	554.2M	581.9M
Cost Of Revenue	16.4M	22.6M	437.4M	459.3M

Total Operating Expenses Cost Of Revenue

Beam Therapeutics fundamental ratios Correlations

	Total Assets	Short Long Term Debt Total	Other Current Liab	Total Current Liabilities	Total Stockholder Equity	Property Plant And Equipment Net	Current Deferred Revenue	Net Debt	Retained Earnings	Accounts Payable	Cash	Non Current Assets Total	Non Currrent Assets Other	Cash And Short Term Investments	Common Stock Shares Outstanding	Non Current Liabilities Total	Other Current Assets	Other Stockholder Equity	Total Liab	Total Current Assets	Short Term Debt	Common Stock	Other Liab	Net Tangible Assets	Other Assets	Net Invested Capital
Total Assets		0.97	0.92	0.99	0.93	0.98	0.93	-0.73	-0.93	0.51	0.85	0.93	0.55	0.94	0.92	0.97	0.77	0.92	0.99	0.94	0.97	0.96	0.93	0.95	0.74	0.93
Short Long Term Debt Total	0.97		0.93	0.99	0.93	1.0	0.92	-0.61	-0.96	0.54	0.76	0.87	0.4	0.94	0.94	0.94	0.88	0.93	0.96	0.94	0.97	0.99	0.88	0.94	0.81	0.93
Other Current Liab	0.92	0.93		0.92	0.87	0.93	0.75	-0.72	-0.87	0.44	0.83	0.89	0.52	0.86	0.87	0.86	0.85	0.87	0.89	0.86	0.87	0.97	0.82	0.9	0.8	0.89
Total Current Liabilities	0.99	0.99	0.92		0.92	0.99	0.94	-0.69	-0.93	0.55	0.82	0.92	0.51	0.93	0.92	0.98	0.81	0.92	0.99	0.93	0.96	0.98	0.91	0.95	0.78	0.93
Total Stockholder Equity	0.93	0.93	0.87	0.92		0.91	0.85	-0.7	-0.98	0.36	0.79	0.85	0.42	0.99	0.89	0.88	0.88	0.99	0.9	0.99	0.93	0.9	0.97	0.98	0.74	0.99
Property Plant And Equipment Net	0.98	1.0	0.93	0.99	0.91		0.92	-0.6	-0.95	0.54	0.75	0.87	0.4	0.93	0.94	0.94	0.86	0.92	0.96	0.93	0.97	0.99	0.87	0.93	0.82	0.92
Current Deferred Revenue	0.93	0.92	0.75	0.94	0.85	0.92		-0.57	-0.89	0.56	0.7	0.83	0.42	0.89	0.84	0.95	0.69	0.87	0.96	0.89	0.92	0.87	0.88	0.88	0.65	0.86
Net Debt	-0.73	-0.61	-0.72	-0.69	-0.7	-0.6	-0.57		0.58	-0.38	-0.98	-0.89	-0.92	-0.65	-0.61	-0.76	-0.39	-0.63	-0.74	-0.65	-0.62	-0.63	-0.78	-0.71	-0.46	-0.69
Retained Earnings	-0.93	-0.96	-0.87	-0.93	-0.98	-0.95	-0.89	0.58		-0.4	-0.7	-0.8	-0.3	-0.99	-0.92	-0.87	-0.92	-0.99	-0.9	-0.99	-0.96	-0.92	-0.93	-0.97	-0.78	-0.97
Accounts Payable	0.51	0.54	0.44	0.55	0.36	0.54	0.56	-0.38	-0.4		0.46	0.55	0.37	0.37	0.67	0.55	0.32	0.3	0.55	0.37	0.57	0.51	0.31	0.34	0.63	0.3
Cash	0.85	0.76	0.83	0.82	0.79	0.75	0.7	-0.98	-0.7	0.46		0.96	0.87	0.76	0.73	0.87	0.52	0.73	0.86	0.75	0.75	0.77	0.85	0.8	0.58	0.78
Non Current Assets Total	0.93	0.87	0.89	0.92	0.85	0.87	0.83	-0.89	-0.8	0.55	0.96		0.79	0.84	0.83	0.96	0.64	0.82	0.95	0.83	0.84	0.88	0.89	0.88	0.72	0.85
Non Currrent Assets Other	0.55	0.4	0.52	0.51	0.42	0.4	0.42	-0.92	-0.3	0.37	0.87	0.79		0.38	0.38	0.64	0.09	0.35	0.59	0.38	0.39	0.43	0.57	0.47	0.29	0.43
Cash And Short Term Investments	0.94	0.94	0.86	0.93	0.99	0.93	0.89	-0.65	-0.99	0.37	0.76	0.84	0.38		0.89	0.9	0.88	0.99	0.92	1.0	0.95	0.91	0.96	0.99	0.73	0.99
Common Stock Shares Outstanding	0.92	0.94	0.87	0.92	0.89	0.94	0.84	-0.61	-0.92	0.67	0.73	0.83	0.38	0.89		0.86	0.83	0.86	0.89	0.89	0.96	0.92	0.81	0.86	0.91	0.85
Non Current Liabilities Total	0.97	0.94	0.86	0.98	0.88	0.94	0.95	-0.76	-0.87	0.55	0.87	0.96	0.64	0.9	0.86		0.69	0.88	1.0	0.89	0.92	0.92	0.92	0.92	0.7	0.89
Other Current Assets	0.77	0.88	0.85	0.81	0.88	0.86	0.69	-0.39	-0.92	0.32	0.52	0.64	0.09	0.88	0.83	0.69		0.9	0.74	0.88	0.81	0.88	0.74	0.87	0.81	0.89
Other Stockholder Equity	0.92	0.93	0.87	0.92	0.99	0.92	0.87	-0.63	-0.99	0.3	0.73	0.82	0.35	0.99	0.86	0.88	0.9		0.9	0.99	0.92	0.91	0.95	0.99	0.73	0.99
Total Liab	0.99	0.96	0.89	0.99	0.9	0.96	0.96	-0.74	-0.9	0.55	0.86	0.95	0.59	0.92	0.89	1.0	0.74	0.9		0.91	0.94	0.94	0.92	0.93	0.73	0.91
Total Current Assets	0.94	0.94	0.86	0.93	0.99	0.93	0.89	-0.65	-0.99	0.37	0.75	0.83	0.38	1.0	0.89	0.89	0.88	0.99	0.91		0.95	0.91	0.96	0.98	0.73	0.99
Short Term Debt	0.97	0.97	0.87	0.96	0.93	0.97	0.92	-0.62	-0.96	0.57	0.75	0.84	0.39	0.95	0.96	0.92	0.81	0.92	0.94	0.95		0.93	0.9	0.92	0.78	0.91
Common Stock	0.96	0.99	0.97	0.98	0.9	0.99	0.87	-0.63	-0.92	0.51	0.77	0.88	0.43	0.91	0.92	0.92	0.88	0.91	0.94	0.91	0.93		0.85	0.93	0.82	0.92
Other Liab	0.93	0.88	0.82	0.91	0.97	0.87	0.88	-0.78	-0.93	0.31	0.85	0.89	0.57	0.96	0.81	0.92	0.74	0.95	0.92	0.96	0.9	0.85		0.97	0.63	0.96
Net Tangible Assets	0.95	0.94	0.9	0.95	0.98	0.93	0.88	-0.71	-0.97	0.34	0.8	0.88	0.47	0.99	0.86	0.92	0.87	0.99	0.93	0.98	0.92	0.93	0.97		0.71	1.0
Other Assets	0.74	0.81	0.8	0.78	0.74	0.82	0.65	-0.46	-0.78	0.63	0.58	0.72	0.29	0.73	0.91	0.7	0.81	0.73	0.73	0.73	0.78	0.82	0.63	0.71		0.71
Net Invested Capital	0.93	0.93	0.89	0.93	0.99	0.92	0.86	-0.69	-0.97	0.3	0.78	0.85	0.43	0.99	0.85	0.89	0.89	0.99	0.91	0.99	0.91	0.92	0.96	1.0	0.71

Click cells to compare fundamentals

Beam Therapeutics Account Relationship Matchups

Beam Therapeutics fundamental ratios Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Total Assets	156.1M	451.7M	1.5B	1.3B	1.5B	794.1M
Other Current Liab	10.3M	91.8M	112.2M	68.2M	122.5M	67.4M
Total Current Liabilities	29.1M	102.3M	213.4M	223.6M	205.6M	126.7M
Total Stockholder Equity	100.9M	245.6M	826.7M	733.5M	981.3M	1.0B
Property Plant And Equipment Net	43.2M	125.4M	187.0M	234.1M	237.8M	132.8M
Net Debt	(11.7M)	(61.9M)	(823.3M)	(53.8M)	(263.2M)	(276.4M)
Retained Earnings	(203.0M)	(397.6M)	(768.3M)	(1.1B)	(1.2B)	(1.1B)
Accounts Payable	7.8M	6.3M	7.5M	9.0M	1.6M	1.5M
Cash	37.2M	162.2M	965.6M	232.8M	435.9M	311.5M
Non Current Assets Total	61.6M	143.4M	508.8M	248.8M	248.7M	193.3M
Non Currrent Assets Other	5.0M	3.1M	309.1M	1.9M	10.9M	10.3M
Cash And Short Term Investments	91.8M	299.7M	965.6M	1.1B	1.2B	1.2B
Common Stock Shares Outstanding	51.3M	46.7M	64.2M	70.0M	77.2M	56.2M
Liabilities And Stockholders Equity	156.1M	451.7M	1.5B	1.3B	1.5B	794.1M
Non Current Liabilities Total	26.0M	103.8M	434.3M	384.6M	272.8M	193.1M
Other Current Assets	2.7M	17.3M	7.4M	14.8M	21.2M	22.2M
Other Stockholder Equity	1.9M	642.6M	1.6B	1.8B	2.2B	2.3B
Total Liab	55.2M	206.1M	647.7M	608.2M	478.4M	319.8M
Total Current Assets	94.5M	308.3M	965.6M	1.1B	1.2B	1.3B
Accumulated Other Comprehensive Income	16K	(9K)	(50K)	(2.4M)	604K	634.2K
Common Stock	73K	573K	684K	712K	816K	458.7K
Other Liab	418K	2.5M	296.5M	214.9M	247.1M	259.5M
Net Tangible Assets	(201.1M)	245.6M	826.7M	733.5M	843.5M	885.7M
Other Assets	18.3M	18.0M	14.5M	14.7M	16.9M	14.8M
Net Invested Capital	(195.4M)	253.0M	832.0M	733.5M	981.3M	1.0B
Capital Stock	302.1M	573K	684K	712K	816K	775.2K
Non Current Liabilities Other	418K	2.5M	34.2M	13.8M	3.0M	2.9M
Net Working Capital	65.4M	206.0M	1.1B	869.3M	1.0B	610.2M
Property Plant Equipment	43.2M	125.4M	187.0M	234.1M	269.3M	282.7M

Building efficient market-beating portfolios requires time, education, and a lot of computing power!

The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.

Try AI Portfolio Architect

When determining whether Beam Therapeutics is a strong investment it is important to analyze Beam Therapeutics' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Beam Therapeutics' future performance. For an informed investment choice regarding Beam Stock, refer to the following important reports:

How To Invest In Beam

Details

Is Beam Stock a good investment?

Details

What is Beam Therapeutics' Net Worth?

Details

Largest Biotechnology Companies

View

Largest Pharmaceuticals, Biotechnology & Life Sciences Companies

View

Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Beam Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in nation.

To learn how to invest in Beam Stock, please use our How to Invest in Beam Therapeutics guide.

You can also try the Performance Analysis module to check effects of mean-variance optimization against your current asset allocation.

Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Beam Therapeutics. If investors know Beam will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Beam Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

Earnings Share

(1.58)

Revenue Per Share

4.273

Quarterly Revenue Growth

(0.17)

Return On Assets

(0.09)

Return On Equity

(0.18)

The market value of Beam Therapeutics is measured differently than its book value, which is the value of Beam that is recorded on the company's balance sheet. Investors also form their own opinion of Beam Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Beam Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Beam Therapeutics' market value can be influenced by many factors that don't directly affect Beam Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

Please note, there is a significant difference between Beam Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Beam Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Beam Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Beam Change In Cash vs Stock Based Compensation Analysis

Change In Cash vs Stock Based Compensation

Change In Cash vs Stock Based Compensation Correlation Analysis

Correlation Coefficient

Change In Cash

Stock Based Compensation

Beam Therapeutics fundamental ratios Correlations

Beam Therapeutics Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Beam Therapeutics fundamental ratios Accounts

Building efficient market-beating portfolios requires time, education, and a lot of computing power!

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Property Plant And Equipment Net	+ 1.0	Short Long Term Debt Total
Total Current Assets	+ 1.0	Cash And Short Term Investments
Total Liab	+ 1.0	Non Current Liabilities Total
Net Invested Capital	+ 1.0	Net Tangible Assets
Total Current Liabilities	+ 0.99	Total Assets
Total Liab	+ 0.99	Total Assets

Total Current Assets	- 0.99	Retained Earnings
Other Stockholder Equity	- 0.99	Retained Earnings
Cash And Short Term Investments	- 0.99	Retained Earnings
Cash	- 0.98	Net Debt
Retained Earnings	- 0.98	Total Stockholder Equity
Net Invested Capital	- 0.97	Retained Earnings